Literature DB >> 21167530

Single focus prostate cancer: pathological features and ERG fusion status.

Sara M Falzarano1, Ming Zhou, Adrian V Hernandez, Eric A Klein, Mark A Rubin, Cristina Magi-Galluzzi.   

Abstract

PURPOSE: We evaluated the clinicopathological characteristics of single focus prostate cancer in radical prostatectomies, its clinical relevance and the occurrence of TMPRSS2-ERG rearrangement.
MATERIALS AND METHODS: We reviewed the records of 1,100 radical prostatectomies and determined the tumor outline and number of cancer foci. When single focus prostate cancer was identified, we recorded pathological characteristics. We assessed ERG fusion status in a subset of cases.
RESULTS: Single focus prostate cancer was identified in 106 radical prostatectomies. Median patient age was 59 years. Median prostate specific antigen was 5.1 ng/ml. Single focus cancer was unilateral in 81% of cases and 98% originated from the peripheral zone. Tumor volume was 0.1 to 3.9 cm(3) (median 0.5). Gleason score was 6 in 38% of patients, 7 in 40%, 8 or greater in 21% and undetermined in 2%. Extraprostatic extension and seminal vesicles invasion were detected in 30% and 2% of cases, respectively. Stage was pT2 in 62% of cases, pT2 with positive margin of resection in 7% and pT3 in 30%. ERG fusion was detected in 68% of tumors. Cases rearranged via deletion had significantly higher tumor volume. Three cases showed intratumor heterogeneity.
CONCLUSIONS: Single focus prostate cancer accounted for 9.6% of tumors. In most cases it involved 1 lobe of the gland and originated from the peripheral zone. Despite a trend toward high grade disease 62% of single focus prostate cancers were organ confined. Only 3 fusion positive cases showed intratumor heterogeneity, suggesting that most single focus cancer may evolve from a single clone of malignant cells. Copyright Â
© 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167530     DOI: 10.1016/j.juro.2010.09.093

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

Review 2.  Clinical potential of the ERG oncoprotein in prostate cancer.

Authors:  Philip Rosen; Isabell A Sesterhenn; Stephen A Brassell; David G McLeod; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2012-02-14       Impact factor: 14.432

3.  ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.

Authors:  Sara Moscovita Falzarano; Ming Zhou; Paula Carver; Toyonori Tsuzuki; Kelly Simmerman; Huiying He; Cristina Magi-Galluzzi
Journal:  Virchows Arch       Date:  2011-07-20       Impact factor: 4.064

4.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

5.  Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Authors:  Sung Han Kim; Soo Hee Kim; Jae Young Joung; Geon Kook Lee; Eun Kyung Hong; Kyung Min Kang; Ami Yu; Byung Ho Nam; Jinsoo Chung; Ho Kyung Seo; Weon Seo Park; Kang Hyun Lee
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

6.  Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Authors:  B Gumuskaya; B Gurel; H Fedor; H-L Tan; C A Weier; J L Hicks; M C Haffner; T L Lotan; A M De Marzo
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-04-02       Impact factor: 5.554

7.  Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.

Authors:  G Schaefer; J-M Mosquera; R Ramoner; K Park; A Romanel; E Steiner; W Horninger; J Bektic; M Ladurner-Rennau; M A Rubin; F Demichelis; H Klocker
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-02-05       Impact factor: 5.554

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.